AlphaBet: Combination of Radium-223 and [(17)(7)Lu]Lu-PSMA-I&T in men with metastatic castration-resistant prostate cancer (clinical trial protocol)

BACKGROUND: [(177)Lu]Lu-PSMA is a radioligand therapy used in metastatic castration-resistant prostate cancer (mCRPC). Despite a survival benefit, the responses for many patients receiving [(177)Lu]Lu-PSMA are not durable, and all patients eventually develop progressive disease. The bone marrow is t...

Descripción completa

Detalles Bibliográficos
Autores principales: Kostos, Louise, Buteau, James P., Yeung, Theresa, Iulio, Juliana Di, Xie, Jing, Cardin, Anthony, Chin, Kwang Y., Emmerson, Brittany, Owen, Katie L., Parker, Belinda S., Fettke, Heidi, Furic, Luc, Azad, Arun A., Hofman, Michael S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9716623/
https://www.ncbi.nlm.nih.gov/pubmed/36465905
http://dx.doi.org/10.3389/fmed.2022.1059122

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9716623/
https://www.ncbi.nlm.nih.gov/pubmed/36465905
http://dx.doi.org/10.3389/fmed.2022.1059122

Ejemplares similares